We are pioneering a new class of medicine we call endobody vaccines that are fully synthetic and train the body to safely and efficiently treat and prevent neurological disease.
We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, CTE and other neurological diseases.
We envision a world where neurodegenerative diseases are prophylactically eradicated.
By The Numbers
80 years ago, it was polio. Today, our epidemic is Alzheimer’s.
CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD
ANNUAL COST TO THE WORLD
Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop vaccines to treat and ultimately prevent Alzheimer’s and other neurological diseases.
We aren’t your average vaccine company.
We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading endobody vaccine technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active vaccine against Alzheimer’s.
United Neuroscience and Boston University Lee Goldstein Laboratory Form Collaboration to Research Tau-Targeted Therapeutics for Treatment and Prevention of Chronic Traumatic Encephalopathy (CTE)
April 16, 2018 -
UNS announced that it has signed a collaboration agreement with the Lee Goldstein laboratory at the Boston University School of Medicine to investigate the potential of Endobody vaccines developed by United Neuroscience to target pathogenic forms of tau proteinRead More
United Neuroscience and University of Texas Southwestern Medical Center Announce Collaboration to Evaluate Endobody Vaccine Candidates Directed at Tau Protein for the Treatment and Prevention of Alzheimer’s Disease
April 11, 2018 -
UNS announced that it has signed a collaboration agreement with the Center for Alzheimer's and Neurodegenerative Diseases at the UTSW Medical Center to identify distinct pathogenic species of tau protein and evaluate promising therapeutic vaccine candidates to contribute to therapies for Alzheimer's and other neurodegenerative diseasesRead More